Ozelle to Debut O-Cyte 1 at ADLM 2026, Bringing Speed to AI-Powered Morphology Intelligence

The upcoming global debut is set to mark a step forward in AI-powered hematology, advancing the 4th Generation of Hematology Analysis

ANAHEIM, Calif. and FRANKFURT, Germany, June 30, 2026 /PRNewswire/ -- Ozelle will unveil O-Cyte 1, its newest automated hematology analyzer, at ADLM 2026 in California. Making its global debut at one of the leading international events for diagnostics and laboratory medicine, O-Cyte 1 marks Ozelle's latest milestone in advancing the 4th Generation of Hematology Analysis through AI × CBM (Complete Blood Morphology).

For decades, cellular morphology has been one of the most valuable sources of hematology insight. Yet bringing morphology into routine hematology workflows without slowing productivity has remained a challenge. Manual microscopy depends on specialist expertise, while image-based approaches have expanded what laboratories can see but have not always fit seamlessly into routine high-throughput workflows.

O-Cyte 1 is designed to address this gap by bringing morphology intelligence, scalable throughput, and operational simplicity into one compact system. Built on Ozelle's AI × CBM technology, the analyzer transforms cell images into structured morphology insight, supporting a workflow that moves beyond numerical parameters toward image-based evidence and consistent interpretation.

Designed for productive clinical workflows, O-Cyte 1 supports up to 60 tests per hour as a standalone unit and up to 360 tests per hour through cascaded expansion. Its compact footprint, modular architecture, minimal-maintenance workflow, and service-ready design are intended to help healthcare providers and laboratory operators improve efficiency while reducing operational complexity.

"O-Cyte 1 reflects our vision of making advanced morphology intelligence more practical, scalable, and accessible for everyday hematology workflows," said Raymond, head of Ozelle North America division. "At ADLM, we look forward to showing global partners how AI-powered morphology can move into more productive hematology workflows."

At ADLM 2026, Ozelle will present O-Cyte 1 alongside its clinical hematology portfolio. As demand grows for efficient and scalable hematology solutions across North America, Europe, the Middle East, Southeast Asia, India, and beyond, Ozelle aims to support diverse clinical settings with AI-powered diagnostic systems designed for everyday practice.

Visitors and partners are invited to experience O-Cyte 1 at Booth 2517 during ADLM 2026, July 28–30, at the Anaheim Convention Center. Partners unable to attend in person are also welcome to request a product briefing and explore regional collaboration opportunities.

Contact Ozelle

www.ozellemed.com
info@ozellepoct.com

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Ozelle to Debut O-Cyte 1 at ADLM 2026, Bringing Speed to AI-Powered Morphology Intelligence

The new CFD instruments give traders early exposure to two of the world's most prominent artificial intelligence companies ahead of anticipated public listings.

DUBAI, UAE, June 30, 2026 /PRNewswire/ -- STARTRADER, a global multi-asset broker, today announced the launch of two new pre-IPO contracts for difference (CFD) products, OPENAIUSD (OpenAI) and ANTHUSD (Anthropic), available for trading from 29 June 2026. The instruments offer 5x leverage and round-the-clock trading access, seven days a week.

The addition of OpenAI and Anthropic to STARTRADER's product suite reflects growing client demand for exposure to high-profile AI technology companies before their public market debuts. As investor interest in AI-sector listings continues to accelerate, STARTRADER enables traders to take positions on these closely watched firms during the pre-IPO window. STARTRADER's move to list both products simultaneously positions the broker among the first to offer retail and institutional traders a direct route to express a market view before shares become available on traditional exchanges.

This strategic launch reflects STARTRADER's commitment to innovation and empowering traders with early access to emerging opportunities. By bridging the gap between high-profile private companies and retail and institutional portfolios, this reinforces STARTRADER's identity as a partner dedicated to the evolving needs of the modern investor.

"AI is shaping the next generation of global industries, and traders want the ability to access these opportunities early. Listing OpenAI and Anthropic as pre-IPO products allows our clients to take a position on two of the most significant companies in this space on their own timeline."
Peter Karsten, Chief Executive Officer, STARTRADER.

The listing of OPENAIUSD and ANTHUSD expands STARTRADER's pre-IPO and thematic CFD catalogue, reinforcing the broker's commitment to giving traders timely access to the companies and sectors shaping global markets.

About STARTRADER

STARTRADER is a global multi-asset broker empowering retail and institutional partners to access global markets through a range of platforms, including MetaTrader, STAR-APP, and STAR-COPY.

Regulated in five jurisdictions (CMA, ASIC, FSCA, FSA, and FSC), STARTRADER combines strong governance with a client-first approach, serving both retail clients and partners with a commitment to transparency, reliability, and long-term growth.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

STARTRADER Launches Pre-IPO Trading Products for OpenAI and Anthropic